- Home
- A-Z Publications
- Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
- Previous Issues
- Volume 10, Issue 4, 2010
Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents) - Volume 10, Issue 4, 2010
Volume 10, Issue 4, 2010
-
-
Editorial [Hot topic:Metal-Containing Drugs and Novel Coordination Complexes in Therapeutic Anticancer Applications - Part I (Guest Editor: Irena Kostova)]
More LessI have been pleased to collect together, at the invitation of the Editor-in-Chief of the Anti-Cancer Agents in Medicinal Chemistry, Professor Michelle Prudhomme, a number of papers from researchers with whose work I am familiar, and in some cases participated in, to contribute to this Special Issue of the Journal. The aims and scope of the special issue of Anti-Cancer Agents in Medicinal Chemistry, entitled “Metal-Containing Dr Read More
-
-
-
Status of Bi- and Multi-Nuclear Platinum Anticancer Drug Development
Authors: Jinchao Zhang, Liwei Wang, Zhiyong Xing, Dandan Liu, Jing Sun, Xiaoliu Li and Ying ZhangCisplatin has become one of the most commonly used compounds for the treatment of a wide spectrum of human malignancies. Unfortunately, cisplatin has several major drawbacks. Driven by the impressive impact of cisplatin on cancer chemotherapy, great efforts have been made to develop new derivatives with improved pharmacological properties. Among the over 30 platinum agents which have entered clinical trial Read More
-
-
-
Latest Insights into the Anticancer Activity of Gold(III)-Dithiocarbamato Complexes
Authors: Luca Ronconi, Donatella Aldinucci, Q. Ping Dou and Dolores FregonaIn this review paper we aim at giving a detailed overview on our research work devoted to the design of gold-based anticancer agents. In particular, during the last decade, we have been developing some gold(III)-dithiocarbamato derivates showing outstanding in vitro and in vivo antitumor properties and reduced, or even no, systemic and renal toxicity, compared to the reference clinically-established anticancer d Read More
-
-
-
A Better Platinum-Based Anticancer Drug Yet to Come?
Authors: Ulrike Olszewski and Gerhard HamiltonIn attempts to overcome the drawbacks of cisplatin - severe toxicity, drug resistance and poor oral bioavailability - the development of platinum-based drugs has progressed from carboplatin and oxaliplatin to the newest generation of drugs, such as satraplatin, picoplatin and the multinuclear platinum complex BBR3464 (triplatin). Despite encouraging preclinical in vitro and in vivo results, outcomes of clinical trials of these coor Read More
-
-
-
Mechanisms of Cytotoxicity of Anticancer Titanocenes
Authors: Ulrike Olszewski and Gerhard HamiltonThe organometallic compound titanocene (bis(cyclopentadienyl)titanium(IV) dichloride) showed promising preclinical anticancer activity in generally resistant tumors in vitro and in vivo but failed in clinical trials. A broad range of analogs with modified cyclopentadienyl ligands conferring increased stability and higher cytotoxicity were developed. Titanium was found to accumulate in the nucleus and inhibit DNA replication and transc Read More
-
-
-
Perspectives for Novel Mixed Diruthenium-Organic Drugs as Metallopharmaceuticals in Cancer Therapy
More LessRuthenium compounds have been actively studied as metallodrugs for cancer therapy. Representatives of ruthenium-based antitumor drugs are the classes of ruthenium(III)-chlorido-(N-ligand) complexes, including the drugs namely NAMI-A and KP1019 in clinical trials, and ruthenium(II)-arene organometallics, with some compounds currently undergoing advanced preclinical testing. An alternative approach for tumor-inhi Read More
-
-
-
Proteomic and Metallomic Strategies for Understanding the Mode of Action of Anticancer Metallodrugs
Authors: Chiara Gabbiani, Francesca Magherini, Alessandra Modesti and Luigi MessoriSince the discovery of cisplatin and its introduction in the clinics, metal compounds have been intensely investigated in view of their possible application in cancer therapy. In this frame, a deeper understanding of their mode of action, still rather obscure, might turn crucial for the design and the obtainment of new and better anticancer agents. Due to the extreme complexity of the biological systems, it is now widely acce Read More
-
-
-
Selenium in the Prevention and Treatment of Hepatocellular Carcinoma
Authors: Altaf S. Darvesh and Anupam BishayeeHepatocellular carcinoma (HCC) happens to be one of the most lethal cancers in the world. Even though most cases occur in the developing world, reported cases in Western Europe as well as North America are on a steep rise. Human HCC etiology includes chronic liver disease, viral hepatitis, alcoholism, iron overload as well as dietary carcinogens such as aflatoxins and nitrosoamines. Surgical resection as well as liver transpla Read More
-
-
-
Boron-Containing Compounds as Preventive and Chemotherapeutic Agents for Cancer
Authors: Romulus I. Scorei and Radu PopaIn the last few years boron (B) compounds became increasingly frequent in the chemotherapy of some forms of cancer with high malignancy and of inoperable cancers. As more B-based therapy chemicals are developed it is necessary to review the correlation between B and the incidence of different forms of cancer, the biochemical and molecular mechanisms influenced by B and to explore the relevance of B in the chemopr Read More
-
Volumes & issues
-
Volume 25 (2025)
-
Volume 24 (2024)
-
Volume 23 (2023)
-
Volume 22 (2022)
-
Volume 21 (2021)
-
Volume 20 (2020)
-
Volume 19 (2019)
-
Volume 18 (2018)
-
Volume 17 (2017)
-
Volume 16 (2016)
-
Volume 15 (2015)
-
Volume 14 (2014)
-
Volume 13 (2013)
-
Volume 12 (2012)
-
Volume 11 (2011)
-
Volume 10 (2010)
-
Volume 9 (2009)
-
Volume 8 (2008)
-
Volume 7 (2007)
-
Volume 6 (2006)
Most Read This Month
Article
content/journals/acamc
Journal
10
5
false
en
